Latest News

March 2010: Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
... more

November 2009: Cellzome Advances Understanding of Hepatitis C ... more

September 2009: Cellzome Announces Achievement of Fourth Milestone in Inflammation Alliance with GlaxoSmithKline ... more

Meet Cellzome at ...

Welcome to Cellzome

home

Cellzome is a privately-owned drug discovery and development company and a leader in the use of chemical proteomics technology. We are using our technology to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Collaboration exploits Cellzome's world-leading proteomics technology in epigenetics
Cambridge, United Kingdom and Heidelberg, Germany, 10th March 2010 - Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere™ technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response. ... more
Heidelberg, Germany, 23rd November 2009 - Cellzome announces that an article published today in Virology has shown that multiple cyclophilins - enzymes that facilitate protein folding - are involved in hepatitis C virus replication. The paper was published by scientists from Cellzome and Novartis Institutes of Biomedical Research (NIBR). In the study, two hepatitis C virus (HCV) drug candidates have been shown to interact with different cyclophilins and thus can attenuate viral replication. Interestingly, the different enzymes are found to participate in different cellular processes, the most prominent one being protein trafficking. ... more
Cambridge, UK and Heidelberg, Germany, 30th September 2009 - Cellzome Inc. announced today that it has successfully achieved the fourth milestone in its strategic alliance with GlaxoSmithKline. The achievement of this milestone triggers a further payment from GlaxoSmithKline. The amounts of these payments are undisclosed. ... more
Integrated chemical genetics and proteomics approach identifies new potential drug targets in Wnt pathway
Heidelberg, Germany, 16th September 2009 - Cellzome announces today, the publication entitled 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling' is now available online in Nature. The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. ... more
Date Conference Location
04 Mar 2010 Liquid Handling and Label Free Technologies London
08-10 Mar 2010 BIOEurope Barcelona
03-06 May 2010 BIO Chicago
06-07 May 2010 Epigenetic World Congress Boston
23-27 May 2010 ASMS Salt Lake City
27-28 May 2010 5th Annual Protein Kinases in Drug Discovery Conference Boston
02-04 Jun 2010 ERBI Annual Conference Cambridge, UK
07-12 Jun 2010 Keystone Conference: Innate Immunity -
Mechanisms Linking with Adaptive Immunity
Dublin
14-15 Jun 2010 4th European Business Development Conference Munich
16-19 Jun 2010 EULAR 2010 Rome